Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly will acquire its longtime research partner Sigilon Therapeutics in a deal worth up to $309.6 million, deepening its bet on encapsulated cell therapy…
Eli Lilly is acquiring longtime partner Sigilon Therapeutics for up to $310 million in cash and contingent value rights, bolstering its type 1 diabetes…
Eli Lilly is buying Sigilon Therapeutics, its partner on a stem-cell-based therapy for type 1 diabetes, for up to $309.6 million. The deal pays $14.92 per…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Lilly agreed to acquire Sigilon for $14.92/share upfront cash (~$34.6M) plus a CVR of up to $111.64/share for total potential consideration up to $309.6M. Builds on the Lilly-Sigilon collaboration since 2018 on encapsulated cell therapies including SIG-002 for T1D. Closed August 14, 2023.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Sigilon Therapeutics Inc. (this deal) | 2023 | $310M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2023 deals · Eli Lilly and Company deals · Metabolic deals